Drug Combination Details
| General Information of the Combination (ID: C07793) | |||||
|---|---|---|---|---|---|
| Name | Betulinic Acid NP Info | + | Erlotinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | RB1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TYMS | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Loss of mitochondrial membrane potential | ||||
| In-vitro Model | HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combining betulinic acid with an EGFR TKI improves drug efficacy in EGFR TKI-resistant lung cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159. | |||
